down arrow

Palisade Bio, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6963892046
USD
1.80
-0.03 (-1.64%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.691.85

52 Week

0.533.30
Valuation
Technical
Day's Volume

CASH

1.31 M

Shareholding (Mar 2025)

FII

0.29%

Held by 3 FIIs

DII

98.7%

Held by 1 DIIs

Promoter

0.00%

How big is Palisade Bio, Inc.?

22-Jun-2025

As of Jun 18, Palisade Bio, Inc. has a market capitalization of 3.09 million and reported net sales of 0.00 million with a net profit of -13.14 million over the last four quarters. Shareholder's funds are at 7.49 million and total assets at 10.88 million.

As of Jun 18, Palisade Bio, Inc. has a market capitalization of 3.09 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -13.14 million during the same period.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds at 7.49 million and total assets at 10.88 million.

Read More

What does Palisade Bio, Inc. do?

22-Jun-2025

Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for unmet medical needs. It has a market cap of $3.09 million and reported a net profit loss of $2 million as of March 2025.

Overview: <BR>Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for diseases of unmet medical need within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 3.09 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.35 <BR>Return on Equity: -246.48% <BR>Price to Book: 0.58<BR><BR>Contact Details: <BR>Address: 20271 Goldenrod Ln Ste 2024, GERMANTOWN MD: 20876 <BR>Tel: 1 301 3664841 <BR>Fax: 1 302 7301370 <BR>Website: https://senecabio.com/

Read More

Who are in the management team of Palisade Bio, Inc.?

22-Jun-2025

As of March 2022, the management team of Palisade Bio, Inc. includes Dr. Kenneth Carter as Executive Chairman and Principal Executive Officer, with board members Dr. Mary Gray, Dr. David Mazzo, Dr. Cristina Csimma, Mr. Scott Ogilvie, and Mr. Sandford Smith, the latter three serving as independent directors.

As of March 2022, the management team of Palisade Bio, Inc. includes Dr. Kenneth Carter, who serves as the Executive Chairman and Principal Executive Officer. Additionally, the board of directors features Dr. Mary Gray, Dr. David Mazzo, Dr. Cristina Csimma, Mr. Scott Ogilvie, and Mr. Sandford Smith, all of whom hold various director positions, with Dr. Csimma, Mr. Ogilvie, and Mr. Smith serving as independent directors.

Read More

Is Palisade Bio, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Palisade Bio, Inc. is in a bearish trend with weak strength, indicated by daily moving averages and bearish signals, despite a mildly bullish weekly MACD, and has underperformed the S&P 500 with a year-to-date return of -63.76%.

As of 9 September 2025, the technical trend for Palisade Bio, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, as indicated by the daily moving averages and the bearish signals from Dow Theory and Bollinger Bands. The weekly MACD shows a mildly bullish trend, but this is overshadowed by the overall bearish indicators. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -63.76% versus the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 5 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.94

stock-summary
Return on Equity

-451.56%

stock-summary
Price to Book

1.99

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
177.65%
0%
177.65%
6 Months
144.57%
0%
144.57%
1 Year
-21.05%
0%
-21.05%
2 Years
-80.17%
0%
-80.17%
3 Years
-97.17%
0%
-97.17%
4 Years
-99.87%
0%
-99.87%
5 Years
-99.94%
0%
-99.94%

Palisade Bio, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Palisade Bio, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Palisade Bio, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength, as indicated by the daily moving averages and the bearish signals from Dow Theory and Bollinger Bands. The weekly MACD shows a mildly bullish trend, but this is overshadowed by the overall bearish indicators. The stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -63.76% versus the S&P 500's 12.22%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-0.20%
EBIT Growth (5y)
-12.30%
EBIT to Interest (avg)
-12.12
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.35
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
12.77%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.63
EV to EBIT
0.28
EV to EBITDA
0.28
EV to Capital Employed
2.08
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
733.08%
ROE (Latest)
-246.48%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (1.01%)

Foreign Institutions

Held by 3 Foreign Institutions (0.29%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -27.27% vs 33.33% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.80",
          "val2": "-2.30",
          "chgp": "-21.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.80",
          "val2": "-2.20",
          "chgp": "-27.27%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -17.07% vs 15.17% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.30",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.90",
          "val2": "-12.80",
          "chgp": "-16.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-0.20",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.40",
          "val2": "-12.30",
          "chgp": "-17.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-51,380.00%",
          "chgp": "5,138.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.80
-2.30
-21.74%
Interest
0.00
0.00
Exceptional Items
-0.00
-0.00
Consolidate Net Profit
-2.80
-2.20
-27.27%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -27.27% vs 33.33% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.30
-100.00%
Operating Profit (PBDIT) excl Other Income
-14.90
-12.80
-16.41%
Interest
0.00
0.00
Exceptional Items
0.00
-0.20
100.00%
Consolidate Net Profit
-14.40
-12.30
-17.07%
Operating Profit Margin (Excl OI)
0.00%
-51,380.00%
5,138.00%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -17.07% vs 15.17% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Palisade Bio, Inc. stock-summary
stock-summary
Palisade Bio, Inc.
Pharmaceuticals & Biotechnology
Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.
Company Coordinates stock-summary
Company Details
20271 Goldenrod Ln Ste 2024 , GERMANTOWN MD : 20876
stock-summary
Tel: 1 301 3664841
stock-summary
https://senecabio.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."